Cellectar Biosciences, Inc. (NASDAQ:CLRB) announces financial results for first quarter of 2017.
Cellectar Biosciences Inc (NASDAQ:CLRB) announces preclinical data that demonstrate the utility of the company’s lead compound, CLR 131, and CLR 125 for use in …
Cellectar Biosciences Inc (NASDAQ:CLRB) announces the United States Patent and Trademark Office has granted a method of use patent for CLR 1501, CLR …
Cellectar Biosciences, Inc. (NASDAQ:CLRB) announces the Japanese Patent Office has granted a method of use patent for two of the company’s phospholipid drug …
Cellectar Biosciences Inc (NASDAQ:CLRB) announces the initiation of a Phase II clinical study of its lead phospholipid drug conjugate (PDC) CLR 131 in patients …
Cellectar Biosciences, Inc. (NASDAQ:CLRB) announces the United States Patent and Trademark Office has granted a method of use patent for CLR 124, the …
Cellectar Biosciences Inc (NASDAQ:CLRB) announces financial results for the year ending December 31, 2016. Management will host a teleconference and live webcast to …
Cellectar Biosciences Inc (NASDAQ:CLRB) announces the Japanese Patent Office has granted a composition of matter patent for the company’s optical imaging phospholipid drug …
Cellectar Biosciences Inc (NASDAQ:CLRB) announces it has entered into a licensing agreement with the Wisconsin Alumni Research Foundation (WARF) for intellectual property rights …
Cellectar Biosciences Inc (NASDAQ:CLRB) investors are overwhelmingly excited this morning after the biopharmaceutical company provided a positive update on its Phase I clinical study …
